Status:
COMPLETED
Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure
Lead Sponsor:
Seoul National University Bundang Hospital
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension
Detailed Description
After taking Amozatan (AMS, amlodipine / rozanthin combination) in patients with essential hypertension, the percentage of patients who reached the mean systolic target blood pressure was evaluated
Eligibility Criteria
Inclusion
- Patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or rosartan monotherapy
- In patients with stage 2 hypertension (SBP 160-179 mmHg), patients requiring a combination therapy to reach the target blood pressure
- Patients who were changed to amosartan while using other hypertensive agents
Exclusion
- Patients with hypersensitivity to dihydropyridine derivatives of amosartan
- Women who are pregnant or who may be pregnant and breastfeeding
- Patients with severe hepatic dysfunction
- Patients with severe aortic stenosis
- Patients at risk of shock
- Patients participating in other clinical studies
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2015
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03255551
Start Date
January 1 2014
End Date
December 31 2015
Last Update
August 21 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.